NEW White Paper - Companion Diagnostic Development: An Overview Discovery's Contribution to AR Microscopy Study Featured in Nature Learn More about Discovery's AI-Annotated FFPE Tissues and DiscoverAI Tissue Analysis NEW Blog Post - Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks NEW Blog Post - Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments NEW Video - Advancing Oligo Therapeutics: Gene Knockdown Studies in Human Hepatocytes

AACR 2025 Resources

Thank you for joining us at the AACR 2025 Annual Meeting. This year’s program included numerous scientific posters and presentations outlining the latest data, insights, and tools driving innovation in cancer research with our extensive biospecimen collection and advanced specialty lab services.

Scientific Posters

Optimization of DNA and RNA extraction from tumor FFPE samples

Neoantigen evaluation in viably cryopreserved dissociated tissue via large scale proteomic profiling

Standardization and validation of CLDN18 antibodies for CLDN18.2 testing in pancreatic cancer: Performance across antibodies and immunohistochemistry platforms

In vitro assays to predict ADC hematological toxicity: Contribution of antibody, linker, and payload

Flash Talks

Discovery experts and strategic partners presented cutting-edge insights, highlighting collaborative efforts to accelerate breakthroughs in the field. Watch the flash talks below.

Shaping the Future of Biomarker Development with Spatial Proteomics on COMET™

Lily Reed
Sr. Technical Sales Specialist
Lunaphore

Do More With Less: Optimized Genomics Workflows Working with Limited Clinical Specimens

Tom Halsey, Ph.D.
EVP Genomics
Discovery Life Sciences

Retrospective Biomarker Testing of a Comprehensive Biorepository to Inform Complex Cohort Development

Shawn Fahl PhD
VP Lab Operations, Cell Services & R&D, Biospecimens
Discovery Life Sciences

An Overview of DiscoverAI and PathExplore

Bahar Rahsepar, Ph.D.
Associate Director of AI Products
PathAI

3D Patient-Derived Tumoroids for Compound and Immune Cell Cytotoxicity Testing

Colin Paul, PhD
R&D Staff Scientist
Thermo Fisher Scientific

TruSight™ Oncology 500 Portfolio – Enabling Comprehensive Genomic Profiling from Liquid and Tissue Biopsy

Pierre Del Moral, Ph.D., MBA
Director Clinical Marketing
Illumina

Xenium: Mapping Spatial Gene Expression with Subcellular Precision

Samantha Shelton, Ph.D.
Science & Technology Advisor
10x Genomics

Expanding the cancer biomarker landscape across plasma and FFPE matrices utilizing Olink^® and mass spectrometry proteomics

Dragana Noe, Ph.D.
Director of Business Development, Mass Spectrometry and Proteomics
Discovery Life Sciences

Biospecimen Breakthroughs: Powering Precision Medicine at Scale with DNAnexus and Discovery Life Sciences

Manbir Sandhu, Ph.D.,
Senior Solutions Engineer
DNAnexus

Unlocking Transcriptomic Insights: High-sensitivity RNA-seq for Oncology Research Applications

Caitlin Gilley
Product Manager
Watchmaker Genomics

Olink^® Reveal expands monitoring of the drug responses in cancer patients

Marijana Rucevic, PhD
Sr Director, Scientific Affairs
Olink

Contact Us Today

Privacy Settings

AACR 2025 Resources

Scientific Posters

Optimization of DNA and RNA extraction from tumor FFPE samples

Neoantigen evaluation in viably cryopreserved dissociated tissue via large scale proteomic profiling

Standardization and validation of CLDN18 antibodies for CLDN18.2 testing in pancreatic cancer: Performance across antibodies and immunohistochemistry platforms

In vitro assays to predict ADC hematological toxicity: Contribution of antibody, linker, and payload

Flash Talks

Contact Us Today

Gentest Services

MARKETS WE SERVE

COMPANY

Markets We Serve

Resources

Popular Keywords

Categories,Pages

Quick Links

Technologies

Development and Clinical Trial Solutions

Our Mission

Technologies

Development and ClinicalTrial Solutions

Post-Approval Services

Development and Clinical
Trial Solutions

Development and Clinical
Trial Solutions